Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Children's Hospital of Philadelphia
With
AbbVie
This is an interventional study of subjects with short bowel syndrome to determine if enteral absorption improves following therapy with pancreatic enzymes. The study will assess enteral absorption and nutritional status at baseline through a series of stool tests, blood tests, and anthropometric measurements. Following approximately ten days of therapy with pancreatic enzymes, the study will reassess enteral absorption.
Age
4–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
history of a small bowel resection with subsequent dependence on parenteral nutrition for at least three months
age 4 years to 65 years
usual state of health for the past two weeks with no medication changes
able to participate in a study for about four weeks with four study visits
able to take pancreatic enzyme medication orally
You may not be if
significant disease other than short bowel syndrome affecting the gastrointestinal tract that impacts absorption or digestions
motility disorder
medications that directly alter fat absorption
cholestatic liver disease defined as a serum conjugated bilirubin greater than 1.0 mg/dL, chronic renal failure, gout, or hyperuricemia
history of a pork allergy
women who are pregnant or lactating
history of fibrosing colonopathy
Those subjects who are eligible for the malabsorption blood test (MBT) test will be excluded if they have a history of a soy or safflower oil allergy.